Drug Profile

Empagliflozin - Boehringer Ingelheim/Eli Lilly and Company

Alternative Names: BI-10773; GIBTULIO; Jardiance; Oboravo

Latest Information Update: 26 Jun 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Boehringer Ingelheim
Developer Boehringer Ingelheim; Duke Clinical Research Institute; Eli Lilly and Company; Kobe University; Medical University of Vienna; Mount Sinai Hospital (Toronto); University of Oxford; Yale University
Class Antihyperglycaemics; Benzhydryl compounds; Cardiovascular therapies; Chlorinated hydrocarbons; Cyclic ethers; Glucosides; Heart failure therapies; Small molecules; Urologics
Mechanism of Action Sodium-glucose transporter 2 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Marketed Cardiovascular disorders; Chronic heart failure; Renal failure; Type 2 diabetes mellitus
Phase III Acute heart failure; Gestational diabetes; Heart failure; Insulin resistance; Type 1 diabetes mellitus
Phase II Decompensated heart failure; Kidney disorders

27 May 2025 Boehringer Ingelheim initiates a phase I trial (In volunteers) (PO) (NCT06962826)
08 May 2025 Boehringer Ingelheim plans phase I trial in healthy volunteers (PO) (NCT06962826)
31 Dec 2024 Mount Sinai Hospital completes phase-III EMPA post-GDM clinical trials in Gestational diabetes in Canada (PO, Capsule) (NCT03215069)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com